Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Meek To Drive M&A At Ipsen, Building On Two Major Launches

Executive Summary

France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.


Related Content

Ipsen's Latest Consumer Health Play: Growth Or Attracting Suitors?
10 Approvals To Watch For In Early 2017
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles
Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting
Ipsen Appoints Baxalta's Oncology Chief Meek CEO
Precision BioSciences Says Baxalta's IO Focus Made It Preferred Partner
Ipsen Pays Exelixis $200m Up Front For Ex-US Cometriq Rights
Ipsen pays Lexicon $23m upfront for ex-US, Japan rights to PhIII drug


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts